Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter August 1, 2020

Plasma xanthine oxidoreductase activity change over 12 months independently associated with change in serum uric acid level: MedCity21 health examination registry

  • Masafumi Kurajoh EMAIL logo , Shinya Fukumoto , Takayo Murase , Takashi Nakamura , Yuki Nagata , Shinya Nakatani , Akihiro Tsuda , Shinsuke Yamada , Tomoaki Morioka , Katsuhito Mori , Yasuo Imanishi , Norifumi Kawada , Kazuto Hirata and Masanori Emoto

Corresponding author: Masafumi Kurajoh, MD, PhD, Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan, Phone: +81-6-6645-3806, Fax: +81-6-6645-3808, E-mail:

Funding source: Sanwa Kagaku Kenkyusho

Funding source: Takeda Pharmaceuticals

Funding source: Astellas Pharma

Funding source: Gout Research Foundation

Funding source: JSPS KAKENHI

Award Identifier / Grant number: 18K11132

  1. Research funding: This study was supported in part by research grants from Sanwa Kagaku Kenkyusho (to M.K.), Taisho Toyama Pharmaceutical Co. (to S.F.), Takeda Pharmaceuticals (to S.F.), Mitsubishi Tanabe Pharma Corporation (to S.F.), Chugai Pharmaceutical Co. (to S.F.) and Astellas Pharma (to S.F.), as well the Osaka City University (OCU) Strategic Research Grant 2014, 2015, 2016 for top priority research (to S.F. and K.H.), a grant-in-aid for scientific research from the Gout Research Foundation (to M.K.), and a JSPS KAKENHI grant (number 18K11132) (to S.F.).

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Ethical approval: The present study was conducted in full accordance with the Declaration of Helsinki, and the present study protocol was approved by the Ethics Committee of Osaka City University Graduate School of Medicine (approval No. 3684).

References

1. Waud, WR, Rajagopalan, KV. Purification and properties of the NAD+-dependent (type D) and O2-dependent (type O) forms of rat liver xanthine dehydrogenase. Arch Biochem Biophys 1976;172:354–64. https://doi.org/10.1016/0003-9861(76)90087-4.Search in Google Scholar PubMed

2. Sakuma, S, Fujimoto, Y, Iwai, M, Fujimoto, K, Yasuda, M, Nishida, H, et al.. Induction of the conversion of xanthine dehydrogenase to oxidase in rabbit liver by Cu2+, Zn2+ and selenium ions. J Pharm Pharmacol 1994;46:487–90. https://doi.org/10.1111/j.2042-7158.1994.tb03832.x.Search in Google Scholar PubMed

3. Murase, T, Nampei, M, Oka, M, Miyachi, A, Nakamura, T. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. J Chromatogr B Anal Technol Biomed Life Sci 2016;1039:51–8. https://doi.org/10.1016/j.jchromb.2016.10.033.Search in Google Scholar PubMed

4. Nakatani, A, Nakatani, S, Ishimura, E, Murase, T, Nakamura, T, Sakura, M, et al.. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients. Sci Rep 2017;7:15416. https://doi.org/10.1038/s41598-017-15419-0.Search in Google Scholar PubMed PubMed Central

5. Kurajoh, M, Fukumoto, S, Emoto, M, Murase, T, Nakamura, T, Ishihara, T, et al.. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 Health Examination Registry. Clin Chem Lab Med 2019;58:780–6.10.1515/cclm-2019-0199Search in Google Scholar PubMed

6. Kurajoh, M, Fukumoto, S, Murase, T, Nakamura, T, Ishihara, T, Go, H, et al.. Insulin resistance associated with plasma xanthine oxidoreductase activity independent of visceral adiposity and adiponectin level: MedCity21 Health Examination Registry. Int J Endocrinol 2019;2019:1762161. https://doi.org/10.1155/2019/1762161.Search in Google Scholar PubMed PubMed Central

7. Yoshida, S, Kurajoh, M, Fukumoto, S, Murase, T, Nakamura, T, Yoshida, H, et al.. Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 Health Examination Registry. Sci Rep 2020;10:4437. https://doi.org/10.1038/s41598-020-61463-8.Search in Google Scholar PubMed PubMed Central

8. Furuhashi, M, Koyama, M, Matsumoto, M, Murase, T, Nakamura, T, Higashiura, Y, et al.. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight. Endocr J 2019;66:777–86. https://doi.org/10.1507/endocrj.ej19-0053.Search in Google Scholar PubMed

9. Saksela, M, Lapatto, R, Raivio, KO. Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol Neonate 1998;74:274–80. https://doi.org/10.1159/000014034.Search in Google Scholar PubMed

10. Carcassi, A, Marcolongo, RJr., Marinello, E, Riario-Sforza, G, Boggiano, C. Liver xanthine oxidase in gouty patients. Arthritis Rheum 1969;12:17–20. https://doi.org/10.1002/art.1780120104.Search in Google Scholar PubMed

Received: 2020-04-22
Accepted: 2020-06-04
Published Online: 2020-08-01
Published in Print: 2021-03-26

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 5.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2020-0563/html
Scroll to top button